Clinical and electrocardiography changes in patients treated with capecitabine

Chemotherapy

Volumn 57, Issue 5, 2012, Pages 381-387

  Koca, Dogan ^a   Salman, Tarik ^a   Unek, Ilkay Tugba ^a   Oztop, Ilhan ^a   Ellidokuz, Hulya ^b   Eren, Murat ^a   Yilmaz, Ugur ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b Institute of Oncology   (Turkey)

Author keywords

Capecitabine; Heart; Side effects

Indexed keywords

CAPECITABINE; DOCETAXEL; IRINOTECAN; LAPATINIB; NAVELBINE; OXALIPLATIN;

ADULT; ANGINA PECTORIS; ARTICLE; ATRIOVENTRICULAR BLOCK; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; COLON CANCER; DYSPNEA; ECG ABNORMALITY; ELECTROCARDIOGRAPHY; FEMALE; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE HYPERTROPHY; HEART PALPITATION; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; SIDE EFFECT; SINUS TACHYCARDIA; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; STOMACH CANCER; TACHYCARDIA; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; DEOXYCYTIDINE; ELECTROCARDIOGRAPHY; FEMALE; FLUOROURACIL; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 80053892292     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000331645     Document Type: Article

References (33)

1. Saif MW, Chu E: Antimetabolites; in DeVita VT, Lawrence TS, Rosenberg SA (eds): De-Vita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott Williams & Wilkins, 2008, vol 1, pp 427-437.
2. Taguchi T, Nakayama T, Masuda N, Yo-shidome K, Akagi K, Nishida Y, Yoshikawa Y, Ogino N, Abe C, Sakamoto J, Noguchi S, Kinki Breast Cancer Study Group: Study of low-dose capecitabine monotherapy for met-astatic breast cancer. Chemotherapy 2010; 56: 16 6-170.
3. Yahalom J, Portlock CS: Cardiac toxicity; in DeVita VT, Lawrence TS, Rosenberg SA (eds): DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott Williams & Wilkins, 2008, vol 1, pp 2678-2688.
4. Scott PA, Ferchow L, Hobson A, Curzen NP: Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction. Emerg Med J 2008; 25:699-700.
5. Coughlin S, Das S, Lee J, Cooper J: Capecitabine induced vasospastic angina. Int J Cardiol 2008; 130:e34-e36.
6. Yeh ET, Bickford CL: Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53: 2231-2247.
7. Monsuez JJ, Charniot JC, Vignat N, Artigou JY: Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010; 14 4: 3-15.
8. Timour Q, Lombard-Bohas C, Slim R, Barel C, Bui-Xuan B, Tabib A, Bricca G, Malonne H, Vial T, Iordescu D, Descotes J: Cardiotox-icity of 5-fluorouracil: report of 6 cases. Therapie 2002; 57: 302-306.
9. Anand AJ: Fluorouracil cardiotoxicity. Ann Pharmacot her 1994; 28: 374-378. (Pubitemid 24105515)
10. Kuropkat C, Griem K, Clark J, Rodriguez ER, Hutchinson J, Taylor SG 4th: Severe cardio-toxicity during 5-fluorouracil chemotherapy: a case and literature report. Am J Clin Oncol 1999; 22:466-470. (Pubitemid 30263293)
11. Sclafani F, Carnaghi C, Colombo P, Bozza-relli S, De Vincenzo F, Rimassa L, Giorgetti PL, Santoro A: Case report of acute aortic dissection duringtreatment with capecit abi-ne for a late recurrence of breast cancer. Chemotherapy 2010; 56: 203-207.
12. Alter P, Herzum M, Soufi M, Schaefer JR, Maisch B: Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 2006; 4:1-5. (Pubitemid 43796695)
13. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, Lom-bard-Bohas C, Duperret S, Belkhiria M, Tabib A, Maujean G, Descotes J, Timour Q: Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 2006; 25: 305-309.
14. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabe-lis A, Tsavaris N: Cardiotoxicit y of f luoropy-rimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 13 4: 75-8 2.
15. Meydan N, Kundak I, Yavuzsen T, Oztop I, Barutca S, Yilmaz U, Alakavuklar MN: Car-diotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol 2005; 35: 265-270. (Pubitemid 41444293)
16. Teixeira L, Ba rry S, Debourdeau P, Cohen A, Tournigand C: Cardiotoxicity of 5-fluoro-uracil. Bull Cancer 2004; 91(suppl 3):154-158.
17. Alter P, Herzum M, Schaefer JR, Maisch B: Coronary artery spasm induced by 5-fluoro-uraci l. Z Kardiol 2005; 94: 33-37. (Pubitemid 40193053)
18. Oztop I, Gencer M, Okan T, Yaren A, Altekin E, Turker S, Yilmaz U: Evaluation of cardio-toxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Jpn J Clin Oncol 2004; 34: 262-268.
19. Luján J, García De Burgos F, Jordán A, G a rcía M, Reyes F, Espinosa MD: Angina related to 5-fluorouracil. Rev Esp Cardiol 2002; 55: 764-767. (Pubitemid 34873973)
20. De Bacquer D, De Backer G, Kornitzer M, Blackburn H: Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women. Heart 1998; 80:570-577. (Pubitemid 28561691)
21. Zairis MN, Manousakis SJ, Adamopoulou EN, Makrygiannis SS, Glyptis MP, Beldekos DJ, Patsourakos NG, Olympios CD, Prekates AA, Foussas SG: Continuous 12-lead elec-trocardiographic ST monitoring and long-term prognosis after successful coronary stenting. Am Hear t J 2006; 151: 892-897.
22. Yilmaz U, Oztop I, Ciloglu A, Okan T, Tekin U, Yaren A, Somali I, Alacacioglu A, Kirimli O: 5-Fluorouracil increases the number and complexity of premature complexes in the heart: a prospective study using ambulatory ECG monitoring. Int J Clin Pract 2007; 61: 795-801. (Pubitemid 46587872)
23. Cardinale D, Sandri MT: Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010; 53: 121-129.
24. Goldsmith YB, Roistacher N, Baum MS: Capecitabine-induced coronary vasospasm. J Clin Oncol 2008; 26: 38 02-3804.
25. Fric k hofen N, Beck FJ, Ju ng B, Fu h r HG, A n-drasch H, Sigmund M: Capecitabine can induce acute coronary syndrome similar to 5-f luorouracil. Ann Oncol 2002; 13: 797-801.
26. Arbea L, Coma-Canella I, Martinez-Monge R, García-Foncillas J: A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. World J Gastroenterol 2007; 13: 2135-2137. (Pubitemid 46795857)
27. Gianni L, Herman EH, Lipshultz SE, Minot-ti G, Sarvazyan N, Sawyer DB: Anthracy-cline cardiotoxicity: from bench to bedside. J Clin Oncol 2008; 26: 3777-378 4.
28. Telli ML, Hunt SA, Carlson RW, Guardino AE: Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007; 25: 3525-3533. (Pubitemid 47310891)
29. Ng M, Cunningham D, Norman AR: The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 2005; 41:1542-1546. (Pubitemid 40981835)
30. Jensen SA, Sørensen JB: Risk factors and prevention of cardiotoxicity induced by 5-fluo-rouracil or capecitabine. Cancer Chemother Pharmacol 2006; 58: 487-493. (Pubitemid 43999797)
31. van Halteren HK, Liem AH, Planting AS: Myocardial ischaemia as a result of treatment with capecitabine. Ned Tijdschr Ge-neeskd 2007; 151: 14 6 9-14 7 3. (Pubitemid 47047256)
32. Manojlovic N, Babic D, Stojanovic S, Filipo-vic I, Radoje D: Capecitabine cardiotoxicity, case reports and literature review. Hepato-gastroenterology 2008; 55:1249-1256.
33. Wijesinghe N, Thompson PI, McAlister H: Acute coronary syndrome induced by capecitabine therapy. Heart Lung Circ 2006; 15:337-339. (Pubitemid 44426248)